Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis

Area of Science:

• Nephrology
• Immunology
• Internal Medicine

Background:

• Diffuse proliferative lupus nephritis often leads to poor renal function prognosis.
• Intravenous methylprednisolone pulses are a proposed treatment for severe nephritis.

Purpose of the Study:

• To compare the efficacy of oral high-dose prednisone versus intravenous methylprednisolone pulses in treating diffuse proliferative lupus nephritis.
• To assess the long-term impact on renal function and identify any differences in side effects.

Main Methods:

• A comparative study involving 15 patients treated with oral prednisone and 7 patients treated with methylprednisolone pulses followed by oral prednisone.
• Both groups received initial prednisone at 2 mg/kg/day.
• Methylprednisolone pulses were administered at 30 mg/kg/day (max 1 gm/day) for six days.

Main Results:

• No deaths occurred in either treatment group.
• Therapeutic side effects were similar between the oral prednisone and pulse therapy groups.
• While pulse therapy demonstrated a more rapid initial improvement in Glomerular Filtration Rate (GFR), long-term renal function outcomes were equivalent for both treatment modalities.

Conclusions:

• Both oral high-dose prednisone and intravenous methylprednisolone pulse therapy are effective in managing diffuse proliferative lupus nephritis.
• The choice of therapy may depend on factors influencing initial GFR response, as long-term renal outcomes are comparable.